The overarching strategic plan of this SPORE is to develop methods for identifying persons at greatest risk for developing lung cancer and then preventing this progression. A second, related component is to understand the """"""""cancer gene anatomy"""""""" required for lung cancer development and then using this information for early detection, prevention, and the selection and/or development of new rational treatments. We have chosen to invest in three central translational research themes: early detection of genetic alterations coupled with chemoprevention in former smokers; identification of persons with an increased inherited risk of developing lung cancer; and developing new methods of smoking cessation by elucidating genetic contributions to nicotine addiction. To achieve these goals our SPORE has assembled clinicians and. basic scientists including medical oncologists, thoracic surgeons, pulmonary physicians, pathologists, molecular geneticists, molecular and cell biologists, epidemiologists, behavioral and psycho-pharmacologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE, brings together two major complementary strengths in lung cancer research involving UT Southwestern Medical Center (UTSW) and M.D. Anderson Cancer Center (UTMDA) in the areas of molecular pathogenesis, genetic epidemiology, early detection, chemoprevention, and smoking cessation/nicotine addiction. This SPORE consists of 5 inter-related projects and 3 supporting Cores. The projects are: I. Gene-Discovery: Identification of 3p Recessive Oncogenes; 2. Genetic Susceptibility; 3. Molecular Early Detection; 4. Chemoprevention in Former Smokers; and 5. Smoking Cessation and the Genetics of Nicotine Addiction. The Cores are: Administrative (A); Pathology and Tissue Resources (B); and Biostatistics/Informatics (C). All of the scientific projects are: translational in nature; focus on human lung cancer; arose out of conjoint planning between UTSW and UTMDA and involve scientists from both institutions as Co-investigators; interact with the other projects; include basic and clinical investigators; and utilize Core resources. Innovative Developmental and Career Development Projects include new methods for gene discovery and therapeutics development. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-05
Application #
6173222
Study Section
Special Emphasis Panel (ZCA1-GRB-L (M1))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
2003-04-30
Budget Start
2000-09-01
Budget End
2003-04-30
Support Year
5
Fiscal Year
2000
Total Cost
$2,224,767
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ng, Patrick Kwok-Shing; Li, Jun; Jeong, Kang Jin et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33:450-462.e10
Cascone, Tina; Gold, Kathryn A; Swisher, Stephen G et al. (2018) Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105:418-424
Kim, Wanil; Shay, Jerry W (2018) Long-range telomere regulation of gene expression: Telomere looping and telomere position effect over long distances (TPE-OLD). Differentiation 99:1-9
Wang, Min; Abrams, Zachary B; Kornblau, Steven M et al. (2018) Thresher: determining the number of clusters while removing outliers. BMC Bioinformatics 19:9
Sinicropi-Yao, Sara L; Amann, Joseph M; Lopez, David Lopez Y et al. (2018) Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC. J Thorac Oncol :
Le, Xiuning; Puri, Sonam; Negrao, Marcelo V et al. (2018) Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 24:6195-6203
Wang, Shidan; Chen, Alyssa; Yang, Lin et al. (2018) Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8:10393
Gomez, Daniel Richard; Byers, Lauren Averett; Nilsson, Monique et al. (2018) Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9:14268-14284
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93
Yamauchi, Mitsuo; Barker, Thomas H; Gibbons, Don L et al. (2018) The fibrotic tumor stroma. J Clin Invest 128:16-25

Showing the most recent 10 out of 1059 publications